Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13254458 | 1.00 | MAPT (0.54) | MAPTCA1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL13254459 | 1.00 | MAPT (0.54) | MAPTCA1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL3486328 | 0.95 | CA1 (0.51) | MAPTCA1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL13254537 | 0.95 | CA1 (0.51) | MAPTCA1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL13254541 | 0.78 | CA1 (0.59) | MAPTCA1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL3486040 | 0.78 | NPSR1 (0.47) | MAPTCA1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL31519362 | 0.78 | MAPT (0.50) | MAPTCA1KDM4E | |
| SCHEMBL28789732 | 0.77 | MAPT (0.68) | MAPTCA1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL14292324 | 0.77 | MAPT (0.68) | MAPTCA1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL7960098 | 0.75 | MAPT (0.47) | MAPTCA1KDM4EHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399684-B2 | Sulfonamide-based organocatalysts and method for their use | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100184986-A1 | SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE | The State of Oregon acting by and through the State Board of Higher Education on behalf of Orego | 2010-07-22 | — | — | US | disclosed |
| WO-2009039181-A2 | SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE | STATE OF OREGON ACTING BY & THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OR. STATE UNIV. (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184986-A1 | SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE | ALDH7A1, SULT1A1, SULT2A1 | MAPT 3451/4885CA1 1253/4885KDM4E 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.